Oral Covid treatment yields promising trial data: drugmakers

San Francisco (AFP) – German pharmaceutical giant Merck and a US partner reported promising results Saturday in trials of a drug administered orally to fight Covid-19, saying it helps reduce patients’ viral load.  “At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data,” said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics. In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called moln…

Read More

HEDGE accordingly